Early Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years of age
• People who have been diagnosed with primary, relapsed, or spread (metastatic) cancer of the liver, bile ducts, or pancreas, confirmed by a tissue sample
• People whose doctors estimate they have a life expectancy of more than 3 months
• People who are reasonably functional in daily life (based on standard performance scoring scales used by doctors)
• People whose standard treatment options have stopped working, or for whom no standard treatment options exist
• People who have a tumour area that doctors can safely sample (biopsy or remove), or who have a body fluid (such as fluid build-up in the abdomen) from which immune cells can be collected
• People who have at least one tumour that can be measured and monitored during the trial
• People whose blood test results (taken within 7 days before joining) meet specific thresholds for white blood cells, infection-fighting cells, immune cells, platelets, haemoglobin, clotting measures, kidney function, liver enzyme levels, and bilirubin levels (confirm specific values with trial site)
• People who have no medical reason preventing them from undergoing a biopsy or minor surgical procedure
• People of childbearing potential who are willing to use highly effective contraception from the time of signing consent and for one year after completing a specific part of the treatment
• People who have stopped any cancer-targeting treatments — including radiotherapy, chemotherapy, or biological therapies — at least 28 days before immune cells are collected
• People who are able to understand and sign the consent form
• People who are able to attend follow-up visits and meet the other requirements of the trial

Who may not be able to join:

• People who need daily steroid medication (such as prednisone) at doses above 15mg per day, or who have autoimmune conditions requiring immune-modifying treatment
• People with significantly reduced lung function based on specific breathing test measurements (confirm details with trial site)
• People with serious heart conditions, such as severe heart failure, significantly low blood pressure, uncontrolled coronary artery disease, very low heart pumping function, or serious heart rhythm or conduction problems
• People who have HIV infection or a positive HIV antibody test, active hepatitis B or C infection, syphilis, or a positive syphilis antibody test
• People with serious physical or mental health conditions
• People who have an active whole-body infection requiring treatment, or who have positive blood cultures or imaging showing signs of infection
• People who have received other treatments — including other medicines, biological therapies, chemotherapy, or radiotherapy — within the past month, or who are currently receiving such treatments
• People with a history of allergic reactions to substances similar to those used in cell-based therapies
• People who have previously received immunotherapy and experienced severe immune-related side effects (rated above Level 3)
• People who still have ongoing side effects from previous cancer treatments that have not returned to a mild or resolved level (with some exceptions, such as hair loss, at the investigator's discretion)
• People who are pregnant or breastfeeding
• People who have previously had an organ transplant, a bone marrow or stem cell transplant from a donor, or kidney replacement therapy (such as dialysis)
• People who the trial doctors consider to have other serious health conditions or other reasons that make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.